Changeflow GovPing Healthcare & Life Sciences Orange Book 46th Edition
Routine Notice Added Final

Orange Book 46th Edition

Email

Summary

The FDA has published the 46th edition of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations). The Orange Book is the authoritative FDA reference listing approved prescription drug products, including patent and exclusivity information used by generic drug manufacturers, pharmacy benefit managers, and healthcare payers to assess therapeutic equivalence.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors Regs.gov: Food and Drug Administration for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 367 changes logged to date.

What changed

The FDA released the 46th edition of the Orange Book, an annual consolidated reference of the agency's approved prescription drug product listings. The Orange Book includes product approval dates, patent and exclusivity information, and therapeutic equivalence evaluations.\n\nGeneric drug manufacturers, pharmacists, and healthcare payers rely on the Orange Book for ANDA filing assessments and formulary decisions. The publication is updated monthly online and consolidated annually into a printed edition.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

Download File

Download

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Notice
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Docket
FDA-2026-P-4112

Who this affects

Applies to
Drug manufacturers Healthcare providers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug product registration Regulatory submission
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Compliance frameworks
GxP
Topics
Healthcare Intellectual Property

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!